DealsApr 13, 2026, 09:26 AM
Xtant Medical Secures Exclusive US Distribution for HEMOBLAST® Bellows
AI Summary
Xtant Medical Holdings, Inc. announced an exclusive distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST® Bellows product in the United States. This FDA-approved topical surgical hemostatic agent will be marketed and sold by Xtant, which has also hired approximately 20 Dilon sales personnel to facilitate its distribution. Dilon will continue manufacturing the product in France.
Key Highlights
- Xtant Medical secured exclusive US distribution rights for HEMOBLAST® Bellows.
- HEMOBLAST® Bellows is an FDA-approved topical surgical hemostatic agent.
- Xtant hired approximately 20 Dilon sales personnel to support product sales.
- Dilon Technologies will continue to manufacture the product in France.